tirzepatide and cancer 💊 Weight-loss drug shows cancer-fighting potential Researchers at the University of Michigan discovered that (Mounjaro, Zepbound), already FDA-approved for diabetes obesity, also shrinks breast tumors in obese mice. When Is it safe for a

When NAPQI levels are higher than the livers capacity to neutralize, NAPQI will form protein adducts on the mitochondria of liver cells

Care at Home: Maintain a robust immune system with SkinCeuticals Immune Support supplements, which contain vitamins and minerals known to enhance immune function

TB 500 increases flexibility, improves blood flow, and speeds recovery by stimulating tissue regeneration

FDA submission is likely coming in 2026/2027 if the remaining readouts hold up Some other noteworthy drugs in the pipeline: Tirzepatide: The base drug is already approved for diabetes and obesity, but Lilly keeps expanding its label Kisunla (donanemab) for Alzheimer's Eloralintide: amylin receptor agonist heading to phase 3, at ADA it showed 20% weight loss on the amylin pathway alone MORF-057: bit of a wild card, after the $3.2 billion acquisition of Morphic